Member Info for Moneymunch

Another 40% plus of shareholding disclosures to come and so every chance of another Major player or two to join the party. DSBM's assessment on the first 60 SFX-01 Covid/Ards patients expected early Q2, ie next month, and so I reckon Huw could have an update or two before that, on the SHP2 cancer target and also the Glioblastoma target and maybe even an update on the breast cancer programme....Exciting times for all invested....there's not many other Bio's around, fully funded with so many shots on multiple targets attracting investment from the leading players in the market....all for 8p a share!!!???? :-)))

They're not here for a quick buck imho, and given the size of their investment, must be supremely confident in Evgen's prospects and potential going forward....the association with Jim Mellon s highly significant and speaks volumes.....More disclosures this coming week and newws from huw at anytime. Gla holders .....Evgen is all set fro growth and is attracting hgh quality shareholders......the market leader in the case of Octopus....On and UP!!! ;-)

We’re part of Octopus Group

Established in 2000, Octopus is a group of businesses investing in people, ideas and industries that change the world.

Yep, a solid substantial long term investment by a market leader, very impressive indeed easyp, and maybe missed by most of the market given the timing of Friday's disclosure.....follow the money.....more disclosures to come this week. Gla ;-)

Who are the 5 most powerful venture capital funds in Britain?

News

9 Feb 2021

The 5 most powerful venture capital funds in Britain in terms of assets under management are: Octopus Investments, Balderton Capital, Atomico, BGF and Highland Europe.

https://www.growthbusiness.co.uk/who-are-the-5-most-powerful-venture-capital-funds-in-britain-2558774/

A very strong indication on why Jim Mellon and maybe Octopus bought in. Gla :-)

NEWS RELEASE 2-FEB-2021

Aging-US: Sulforaphane promotes C. elegans longevity and healthspan

"The results in this Aging-US research output, indicate that sulforaphane prolongs the lifespan and healthspan of C. elegans through insulin/IGF-1 signaling."

...............

Here, the authors asked whether sulforaphane may influence the lifespan and healthspan of C. elegans.

They found that sulforaphane significantly extends the lifespan of C. elegans and delays age-related phenotype changes.

The analysis of wild-type C. elegans and 9 mutant strains revealed that sulforaphane inhibited DAF-2 insulin/insulin receptor signaling and thereby increased DAF-16 nuclear translocation, resulting in the expression of the sod-3, mtl-1 and gst-4 target genes, which are known mediators of longevity in C. elegans.

The Herr Research Team concluded in their Aging-US Research Paper, "we are the first to report that sulforaphane prolongs the lifespan and increases the healthspan of C. elegans through the inhibition of DAF- 2/insulin/IGF-1 signaling and the activation of DAF- 16/FOXO nuclear transcription in C. elegans. Our study provides a promising hint regarding the suitability of sulforaphane as a new anti-aging drug. However, additional studies in invertebrates and mammalian model organisms are necessary to expand our findings."

https://www.eurekalert.org/pub_releases/2021-02/ijl-asp_1020221.php

Boom time - Jim Mellon

Longevity science will, I think, lead to the biggest stock market boom ever. It will make the recent medical cannabis boom look like nothing. For the first time in the history of mankind, the elixir of youth, the promise of living a longer life, will actually come true.

There is no one pill that you can take, but a combination of several pharmaceuticals, gene therapies, gene-related technology and treatments could extend your lifespan to 120.

I’m confident in predicting that the science of longevity will represent the biggest industry on the planet within 20 years, and that it will be affordable for everyone after about ten years of commercial exploitation.

Wear and tear

It is important to note that we’re not predestined to die. But as time goes on, the healing process of our body gets overwhelmed – wear and tear overwhelms repair.

We gradually go into a process called ‘loss of homeostasis’, which signals that our inner chemical balance is beginning to get upset, which eventually results in death.

There are some creatures out there, such as the C. elegans worm, which Google’s ageing company Calico is studying, that are made up of atoms and molecules just like us but don’t die naturally. Science has shown that the lifespan of a worm can be increased by up to 20 times using genetic manipulation.

Similar principles can apply to humans. There is a huge amount of bioscience activity in the UK, which is not widely known. There have been negative developments in the form of Neil Woodford’s investments and the government’s lack of funding in this area.

But now people like Sir John Bell are spearheading major efforts to build a home-grown industry. Increasingly, the nexus between VC universities and scientist-entrepreneurs that’s made the US so successful in this field is developing in the UK.

More Juvenescence employees are based here than anywhere else, so we’re very much British. It’s very important to us that the UK retains its status as the second major centre for life sciences in the world.

For any newbies looking in for the first time, Jim Mellon is the Chairman of Juvensescene who signed a licensing agreement with Evgen 15/9/20, and so maybe one of the many possible reasons why Octopus have bought 21.8m shares representing 7.96%......Exciting times....Gla ;-)

Details of the Agreement

The license is for exclusive rights to exploit certain patents and know-how for all non-pharmaceutical applications in the United States, with options for the other major markets namely, Europe, Asia and the Rest of the World. Evgen will receive upfront and milestone payments of up to $10.5m, and in addition, royalties on sales. Evgen received an initial payment of $250k on signing of the Agreement.

Barry Clare, Executive Chairman of Evgen, said: "This deal is a strong demonstration of the broad potential for our sulforaphane platform and achieves monetisation in an area which is outside our focus of therapeutic development in the Nrf2 and STAT3 pathways. Juvenescence has a science-driven approach to nutritional health products and brings in-depth experience in this sector. We are delighted to have them as a partner. "

Colin Watts, Chief Executive Officer of JuvLife Division, said : "We are pleased to reach an agreement with Evgen to leverage their scientific technology and expertise to create a differentiated and innovative new product for the global consumer nutritional health market. Juvenescence has built a reputation as a broad-based healthcare company in the Longevity space through strong partnerships with scientific leaders in their specific areas and we are delighted to have such a partner in Evgen."

https://uk.advfn.com/stock-market/london/evgen-pharma-EVG/share-news/Evgen-Pharma-PLC-Licence-agreement-with-Juvenescen/83256314

As far as her views on Longevity as a sector goes, Choudry has spent time with Juvenescence’s Jim Mellon and the people who manage his investment funds.

“There were interesting views on lifespan versus health span, and we asked ourselves whether Longevity is a space we should be looking at?” she says. “We think it is because the areas that we want to look at are those where we think there is a large opportunity or big global challenges that we could be solving. Longevity certainly ticks that box, the aging population is something that is at the front of our mind. Probably more so around health span rather than lifespan – how are these people able to keep good health into their later years. Those are some of the areas that we are looking at within our future of health team.”

https://www.longevity.technology/biohacking-and-the-future-of-health-and-longevity/

0  0 0

Octopus Investments Octopus Venutures, all part of the Octopus Group, who now hold 8% of Evgen...I wonder if Jim Mellon has bought in??? Gla ;-)

Biohacking and the future of health and Longevity

February 14, 2020

Talking investment with Octopus Ventures’ Uzma Choudry and what she’s looking for in a breakthrough technology.

Next week, the first Biohacking Congress will be held in London, bringing together famous biohackers, renowned scientists, healthcare professionals, researchers, authors and investors focused on helping us all live a longer and healthier life.

A key component of the event is a start-up competition, which is part of the Startup World Cup, a global competition with a grand prize of $1 million. Seed and Series A level start-ups from MedTech, digital health, biotech and healthcare will pitch to a panel of experts at Biohacking Congress, including Uzma Choudry, PhD, an investor at Octopus Ventures.

With more than £1 billion under management today, Octopus Ventures started out as a generalist Venture Capital (VC) firm, but in recent years has focused on three key pillars of investment: Deep Tech, Future of Money and Future of Health.

Uzma is focused on assessing investment opportunities, conducting preliminary due diligence and executing deals. Her experience straddles the Deep Tech and Future of Health Pods, and she is now focused on Frontier Technologies within health and biotech such as synthetic biology and nanotech, genomics, gene editing and computational biology. This includes platforms at the intersection of technology and biology, including human augmentation and neurotech.

“We’re starting to build more expertise in the frontier technologies within health and seeing a number of life sciences opportunities which fit in that bracket,” she says. “And that’s where we feel there’s an overlap between deep tech and health.”

“… we asked ourselves whether Longevity is a space we should be looking at? … We think it is because the areas that we want to look at are those where we think there is a large opportunity or big global challenges that we could be solving. Longevity certainly ticks that box …”

 

In terms of biohacking specifically, Choudry, with a PhD in synthetic biology and biophysics, has a keen personal interest. She points at the opportunity presented by advancements in the genomics space – initially around the ability to read the “biological” software (genome) through more cost-effective DNA sequencing technology, but further now in developments around gene editing tools, such as CRISPR-Cas3/9, which provide the ability to write and edit the software/genes, and opening up a massive opportunity.

0  0 0

Definitely "high quality" ...Gla :-)

Trusted financial solutions

UK’s largest provider of VCTs, EIS and BPR-qualifying investments

£9.1 billion under management*

120+ investment professionals

*At 30 September 2020

We’re part of Octopus Group

Established in 2000, Octopus is a group of businesses investing in people, ideas and industries that change the world. You might know us through our energy company, Octopus Energy. Learn more at octopusgroup.com.

First of many disclosures....hopefully a few bigger ones to come. Gla :-)

Lol....yep it is a paultry amount of shares, although exactly what he was entitled to in relation to his shareholding. :-)

I'm with ii as well, mine popped up an hour or so before close, full allocation and around 65% additional, no refund yet on the shares I didn't get and so maybe tomorrow. Gl :-)

Evgen Pharma raised £11m to fund/progress SFX-01 to key valuation inflection points that will provide a cash runway until at least mid-2023.

LifeArc’s selection of SFX-01 and funding of a 300- patient Phase II/III trial in Acute Respiratory Distress Syndrome (ARDS), including COVID-19 patients, is a significant endorsement of SFX-01’s potential value, with near-term interim safety and futility data analysis expected in Q2 2021.

Additionally, Evgen should have potentially three Phase II-ready programmes by
year-end 2021, a platform technology that can translate into further investigator led studies and a royalty stream from the application of Sulforadex as a delivery vehicle in non-pharma applications (up to $10.5m milestones plus royalties).

With this number of shots on goal, any one of which would be significant, we increase our SOTP rNPV-based target price to 29p with a bear/bull scenario of 15-52p.

Placing raised £11m by way of the issue of up to 137.5m shares at 8p, representing 50.0% of the enlarged equity.

Net funds will be used for

(i) additional preclinical studies,

(ii) a glioma clinical trial,

(iii) formulation and scale-up manufacturing for SFX-01 and

(iv) work to file an IND for SFX-01 in the US.

This will provide a cash runway to mid-2023 and through multiple valuation inflection points.

Novel molecule that has been shown to directly modulate at least three unrelated
mechanistic targets; Nrf2, STAT3 and more recently SHP2, resulting in Evgen targeting four diseases in cancer and inflammation, all with high unmet clinical needs.

Acute Respiratory Distress Syndrome (ARDS) +/- COVID-19

The trial design includes an assessment of safety and futility by a Data Safety and Monitoring Board ("DSMB") who will review unblinded data on the first 100 patients treated. In addition to the DSMB safety and futility assessment, Dundee University ("the Sponsor") has decided to review the top-level unblinded data in a preliminary assessment of possible efficacy.

This may lead to adjustments to the design of the trial for remaining patients, including in patient numbers, and possibly early termination for either safety, futility or alternatively, strong efficacy. It is expected that this initial data will be available during the second quarter of calendar 2021.

The Sponsor has also requested that the DSMB review data from the first 60 patients solely for safety and this process will be starting shortly. The outcome of this is expected to be available in early Q2 2021.

Pre-clinical data updates in H1 2021 should provide the clarity for Evgen’s positioning of SFX-01 in breast cancer (eg. CDK4/6 resistant tumours), glioma (brain cancer) and a third undisclosed oncology indication and the evidence to partners for monetisation events.

Not without risk, but multiple shots on goal provide investors substantial upside potential, given the number of opportunities that exist for monetising SFX-01 and Sulforade

Maybe and maybe not, the majority of the £10m placing shares have probably gone to existing Major Shareholders who are here for the long term, and the "number of new, high quality shareholders to Evgen's share register ( presumably those holding at least 3% ) and already given a warm welcome by Huw will no doubt be more interested Evgen's longer term prospects imho.......and diclosure of the new investors could also be very well received imho.....and Huw could have plenty of updates from the pipeline to report in the coming days which could drive the sp North, and with Evgen fully funded for the next couple of years with multiple shots on multiple targets, it has become a very attractive investment, and so i reckon 8p will be a distant memory before you know it......Gla ;-)

Exciting times ahead from a fully funded Evgen, in anticpation of a flow of positive news from Huw in the coming days, weeks and months. Gla ;-)

Commenting on the Fundraising, Huw Jones, CEO of Evgen Pharma plc, said:

"This heavily oversubscribed fundraising is transformative for us and allows us to accelerate both our future clinical and current pre-clinical work dramatically, together with expanding our senior management team to support our growth. We are very pleased with recent progress of our work on SFX-01 and are most grateful for the support shown in this placing by existing shareholders. The Placing also brings a number of new, high quality shareholders to our register and we offer a warm welcome to them as we accelerate our progress in a range of cancers and acute respiratory distress."

Presumably within the next couple of weeks for those holding 3% or more , and all existing Major shareholders will also report disclosure of their new share % holding commensurate to the new enlarged share capital. We already know that Intuitive Investors Plc have participated for a couple of million plus through their own press release, but doesn't require reporting here as no threshold has been crossed. Gl ;-)

3 March 2021

Evgen Pharma plc

("Evgen Pharma" or "the Company")



Result of Open Offer



Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, is pleased to announce the results of its Open Offer.

On 2 February 2021, Evgen announced its intention to raise gross proceeds of up to £11 million by way of a Placing and Open Offer, all at an issue price of 8 pence per New Ordinary Share. A total of 137,490,676 New Ordinary Shares will be issued at the Issue Price (subject to the conditions noted below), of which, 12,490,676 New Ordinary Shares will be issued pursuant to the Open Offer. This brings the gross proceeds of the Fundraising to approximately £11 million before expenses.

The Open Offer closed for acceptances at 11.00 a.m. yesterday. The Company has received valid acceptances from Qualifying Shareholders in respect of their Basic Entitlements in respect of 5,389,931 New Ordinary Shares, representing approximately 43 per cent. of the Open Offer Shares. In addition, the Company has received applications from Qualifying Shareholders under the Excess Application Facility in respect of 14,359,431 New Ordinary Shares, representing a total over-subscription of approximately 58 per cent. of the available Open Offer Shares. Accordingly, Qualifying Shareholders who have validly applied for Open Offer Shares will receive their full Basic Entitlements. As applications under the Excess Application Facility cannot be satisfied in full, applications for New Ordinary Shares under the Excess Application Facility will be scaled back in accordance with the terms set out in the Circular.

General Meeting

The Fundraising remains conditional on the approval by Shareholders of the Resolutions at the Company's General Meeting to be held at 10:00 a.m. today (or any adjournment thereof), the satisfaction of certain conditions in the Placing Agreement and Admission of the New Ordinary Shares to trading on AIM occurring at or before 8.00 a.m. on 4 March 2021 (or such later date as the Company and finnCap may agree, being not later than 8.00 a.m. on 18 March 2021).

The Company will announce the results of the General Meeting as soon as practicable after the meeting concludes.

Following the placing , there will be 262m shares and so 6.65p would equate to a market cap of £17m, yet Evgen will have c£13m cash in the bank...I reckon you're going to be waiting a while before you see 6.65p, especially with a few good updates from Huw which are bound to follow, not to mention disclosure of the "new high quality investors" who obviously hold Evgen in higher regard . Gla holders...Evgen are all set for Go!!! :-)

Up yours mate, you're also the dipstick that proclaimed that Evgen's science is a scam.....and popped up as kingoaf on Lse and Advfn to troll me....remember???